Document Detail


Use of Impella Recover 2.5 left ventricular assist device in patients with cardiogenic shock or undergoing high-risk percutaneous coronary intervention procedures: experience of a high-volume center.
MedLine Citation:
PMID:  18614983     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIM: Percutaneous coronary interventions are increasingly applied to high-risk patients. The availability of hemodynamic support devices offers a promising option to prevent and treat low-output syndrome in these patients. The aim of this study was to evaluate the feasibility, safety and efficacy of the Impella Recover'' LP 2.5 left ventricular assist device in patients with cardiogenic shock or undergoing high-risk percutaneous coronary interventions. METHODS: Eleven patients presenting cardiogenic shock (N=6) or scheduled for high-risk percutaneous revascularization (N=5) were evaluated. The Impella pump was successfully implanted in all patients, except one. When implanted, the device was correctly positioned in the left ventricle and remained in a stable position. RESULTS: Bleedings occurred in 7 patients (5 of them presented cardiogenic shock), while renal failure and severe thrombocytopenia were observed in 4 and 1 patients respectively, all with cardiogenic shock. During high-risk procedures, the Impella pump succeeded in obtaining hemodynamic stability, while in only two patients with cardiogenic shock the device determined a significant improvement of hemodynamic variables. All elective patients and two patients with cardiogenic shock were discharged from the hospital and were still alive at 30-day follow-up. CONCLUSION: These data, although preliminary due to the limited sample size, demonstrated the feasibility, safety and efficacy of the Impella Recover LP 2.5 during high-risk percutaneous procedures, even though the benefits of prophylactic deployment of such a system have to be further investigated. The use of Impella Recover LP 2.5 in patients with cardiogenic shock is feasible and safe, however it maybe insufficient in reversing an advanced cardiogenic shock which, probably, has to be treated with more powerful left ventricular assist devices.
Authors:
S Vecchio; T Chechi; G Giuliani; A Lilli; L Consoli; G Spaziani; F Giannotti; M Margheri
Related Documents :
15126133 - Biochemical analysis of saliva and taste acuity evaluation in patients with burning mou...
8582923 - Self-inflicted patient burns: suicide versus mutilation.
6887163 - A systematic controlled study of pulmonary abnormalities in rheumatoid arthritis.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Minerva cardioangiologica     Volume:  56     ISSN:  0026-4725     ISO Abbreviation:  Minerva Cardioangiol     Publication Date:  2008 Aug 
Date Detail:
Created Date:  2008-07-10     Completed Date:  2009-01-27     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0400725     Medline TA:  Minerva Cardioangiol     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  391-9     Citation Subset:  IM    
Affiliation:
Unit of Cardiology and Invasive Cardiology 2, Careggi Hospital, Florence, Italy. sabinevecchio@gmail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Coronary Syndrome / surgery*
Aged
Aged, 80 and over
Angioplasty, Transluminal, Percutaneous Coronary*
Feasibility Studies
Heart-Assist Devices*
Humans
Male
Middle Aged
Risk Factors
Shock, Cardiogenic / surgery*

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The long QT syndrome in pediatric age: prognosis and risk factor.
Next Document:  Experimental-clinical study on the effects of hydromassage with Thermae Oasis's salsobromoiodine wat...